Tempest Therapeutics, Inc. SEC filings TPST
Tempest Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 1, 2013. Its latest annual report, Form ARS, was filed on Nov 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 26, 2026 | Nov 9, 2026 |
| DEFA14A | Additional proxy material | Oct 20, 2026 | — |
| PRE 14A | Preliminary proxy statement | Oct 16, 2026 | Nov 9, 2026 |
| DEFA14A | Additional proxy material | Sep 16, 2026 | — |
| DEFA14A | Additional proxy material | Aug 18, 2026 | — |
| DEFA14A | Additional proxy material | Jul 28, 2026 | — |
| DEF 14A | Proxy statement | Jul 17, 2026 | Jul 27, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 7, 2026 | Jul 27, 2026 |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jun 18, 2026 |
| PRE 14A | Preliminary proxy statement | May 29, 2026 | Jun 18, 2026 |
| DEF 14A | Proxy statement | Dec 31, 2025 | Jan 27, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 2, 2025 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Nov 19, 2025 | — |
| DEF 14A | Proxy statement | Nov 12, 2024 | Dec 3, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 29, 2024 | Dec 3, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 13, 2024 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | Jun 15, 2023 |
| DEFA14A | Additional proxy material | May 26, 2022 | — |
| DEFA14A | Additional proxy material | May 9, 2022 | — |
| DEFA14A | Additional proxy material | May 9, 2022 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 17, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 22, 2022 | Jun 17, 2022 |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 19, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 11, 2019 |
| DEFA14A | Additional proxy material | Nov 30, 2018 | — |
| DEFA14A | Additional proxy material | Nov 19, 2018 | — |
| DEFM14A | Filing | Nov 6, 2018 | — |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 26, 2018 |
| DEFA14A | Additional proxy material | Apr 26, 2017 | — |
| DEF 14A | Proxy statement | Apr 26, 2017 | Jun 8, 2017 |
| DEFA14A | Additional proxy material | Apr 18, 2016 | — |
| DEF 14A | Proxy statement | Apr 18, 2016 | Jun 2, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEFA14A | Additional proxy material | Apr 20, 2015 | — |
| DEF 14A | Proxy statement | Apr 20, 2015 | Jun 4, 2015 |
| DEFA14A | Additional proxy material | Apr 30, 2014 | — |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 13, 2014 |
| DEFA14A | Additional proxy material | Apr 30, 2013 | — |
| DEFA14A | Additional proxy material | Apr 26, 2013 | — |
| DEF 14A | Proxy statement | Apr 26, 2013 | Jun 7, 2013 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TPST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.